AbbVie Inc (ABBV)

ABBV (NYSE:Drugs) EQUITY
$64.74
neg -0.32
-0.49%
Today's Range: 64.27 - 65.43 | ABBV Avg Daily Volume: 8,057,100
Last Update: 08/25/16 - 4:00 PM EDT
Volume: 6,366,484
YTD Performance: 9.82%
Open: $65.04
Previous Close: $65.06
52 Week Range: $45.45 - $68.12
Oustanding Shares: 1,628,542,359
Market Cap: 107,760,647,895
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 7 8
Moderate Buy 0 0 0 1
Hold 6 6 6 3
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.23 2.23 2.14 1.81
Latest Dividend: 0.57
Latest Dividend Yield: 3.45%
Dividend Ex-Date: 07/13/16
Price Earnings Ratio: 19.07
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
19.07 19.10 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
7.18% 2.54% 49.80%
GROWTH 12 Mo 3 Yr CAGR
Revenue 14.50 0.20 0.07
Net Income 190.00 0.00 -0.01
EPS 184.50 -0.10 -0.02
Earnings for ABBV:
EBITDA 8.37B
Revenue 22.86B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $1.20 $1.19 $4.81 $5.71
Number of Analysts 8 6 9 10
High Estimate $1.22 $1.23 $4.83 $6.01
Low Estimate $1.17 $1.14 $4.77 $5.35
Prior Year $1.13 $1.13 $4.29 $4.81
Growth Rate (Year over Year) 5.86% 5.46% 12.02% 18.88%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

James Passeri

 | Aug 18, 2016 | 11:55 AM EDT

RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.

By

Bret Jensen

 | Aug 12, 2016 | 10:00 AM EDT
Small biotech tanked on weak earnings, but still seems promising.
By

David Katz

 | Aug 5, 2016 | 7:00 AM EDT
Rarely do investors get to buy these types of quality businesses at such discounted prices.
By

Bret Jensen

 | Aug 2, 2016 | 11:00 AM EDT
The sector seems to be rebounding after tumbling by more than 40%.
By

James Passeri

 | Aug 1, 2016 | 5:05 PM EDT
The drug maker continued to rally Monday.
By

Bret Jensen

 | Aug 1, 2016 | 1:00 PM EDT
The bifurcation can be seen just by looking at Apple's recent results.
By

Bruce Kamich

 | Jul 29, 2016 | 3:09 PM EDT
Consider raising your sell stop protection to a close below $61.
By

Anders Keitz

 | Jul 29, 2016 | 1:23 PM EDT
The Anheuser-Busch InBev and SABMiller deal is another step closer to completion.
By

David Katz

 | Jul 27, 2016 | 7:00 AM EDT

It's too cheap for a biotech giant with years of patent protection for its key products and great cash flow.

By

David Katz

 | Jul 6, 2016 | 7:00 AM EDT

Valuations are stretched in certain names and industries, so some profit-taking appears in order.

We have followed all areas of the Healthcare industry for decades. And while there are lik...
Shares of Dollar General (DG) got hammered today after fiscal Q2 EPS came in at $1.08 vers...
Before the open today, I noted to our members that crude oil is starting to look and act l...
Stocks continue to meander in very narrow ranges as investors appear hesitant to make any ...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.